The global demand for Transdermal Drug Delivery Systems Market is presumed to reach the market size of nearly USD 84.58 MN by 2028 from USD 56.62 MN in 2021 with a CAGR of 5.9% under the study period 2022 - 2028.
A transdermal drug delivery system is a self-contained discrete dosage form that will deliver the drug at a controlled rate for systemic circulation when applied to the intact skin. The transdermal drug delivery system is also known as a transdermal patch or skin patch. The transdermal drug delivery system is a patient-friendly and painless device. It can deliver drugs with a short-half-life time more easily and are well adapted to eliminate frequent administrations to maintain constant drug delivery. The system has many advantages such as longer therapeutic impact, fewer side effects, increased bioavailability, enhanced patient compliance, and ease of medication therapy termination.
Market Dynamics
Technological improvements in transdermal drug delivery systems and the high prevalence of chronic diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases drive the market for the transdermal drug delivery system. The increasing inclination of patients and physicians toward pain-free drug delivery has led to a significant increase in the market’s growth potential. The growing use of contraceptives, and the development of new adhesives, penetration enhancers, and molecular absorption enhancers, are forecast to contribute to the market growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of transdermal drug delivery systems. The growth and trends of transdermal drug delivery systems industry provide a holistic approach to this study.
Market Segmentation
This section of the transdermal drug delivery systems market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Applications
- Pain Management
- Hormonal Applications
- Central Nervous System Disorders
- Cardiovascular Diseases
- Other Applications (Diabetes, Smoking Cessation, Motion Sickness, Overactive Bladder)
By Type
- Transdermal Patches
- Transdermal Semisolids
By End Users
- Home Care Settings
- Hospitals & Clinics
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Transdermal Drug Delivery Systems market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Transdermal Drug Delivery Systems Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the transdermal drug delivery systems market include Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK). Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
